Incyte Corporation (INCY)
FDA Applications
Note: This list only includes applications that have been responded to by the FDA.
| Application | Product Name | Active Ingredient | Form | Strength | Status | ||
|---|---|---|---|---|---|---|---|
| BLA761411 - INCYTE CORP | |||||||
| NIKTIMVO | axatilimab-csfr | INJECTABLE;INTRAVENOUS | 50 MG/ML | Prescription | |||
| BLA761334 - INCYTE CORP | |||||||
| ZYNYZ | RETIFANLIMAB-DLWR | INJECTABLE;INTRAVENOUS | 500MG/20ML(25MG/ML) | Prescription | |||
| NDA215309 - INCYTE CORP | |||||||
| OPZELURA | RUXOLITINIB PHOSPHATE | CREAM;TOPICAL | EQ 1.5% BASE | Prescription | |||
| NDA213736 - INCYTE CORP | |||||||
| PEMAZYRE | PEMIGATINIB | TABLET;ORAL | 9MG | Prescription | |||
| PEMAZYRE | PEMIGATINIB | TABLET;ORAL | 13.5MG | Prescription | |||
| PEMAZYRE | PEMIGATINIB | TABLET;ORAL | 4.5MG | Prescription | |||
| NDA202192 - INCYTE CORP | |||||||
| JAKAFI | RUXOLITINIB PHOSPHATE | TABLET;ORAL | EQ 5MG BASE | Prescription | |||
| JAKAFI | RUXOLITINIB PHOSPHATE | TABLET;ORAL | EQ 15MG BASE | Prescription | |||
| JAKAFI | RUXOLITINIB PHOSPHATE | TABLET;ORAL | EQ 20MG BASE | Prescription | |||
| JAKAFI | RUXOLITINIB PHOSPHATE | TABLET;ORAL | EQ 25MG BASE | Prescription | |||
| JAKAFI | RUXOLITINIB PHOSPHATE | TABLET;ORAL | EQ 10MG BASE | Prescription | |||